Hi Koo.

My feeling on this derives from the advanced epigenetic platforms developed by Resverlogix and spun into Zenith. I do think at some point the scientific and investment communities are going to catch on to epigenetics and both the specific epigenetics of both Zenith and RVX and then there could be a huge explosion in perceived value.

So there is huge synergy between the 2 - one (rvx-208) for CVD, diabetes mellitus, chronic kidney disease, dimencia, etc AND the other (Zenith) for cancer in terms of solid tumours and hematological cancers at this stage.

IMHO

Toinv